This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tse, K C Articles by Chan, T M Search for Related Content PubMed PubMed Citation Articles by Tse, K C Articles by Chan, T M Social Bookmarking                   What's this?

Quality of life comparison between corticosteroidand-mycofenolate mofetil and corticosteroidand-oral cyclophosphamide in the treatment of severe lupus nephritis

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

C SO Tang

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

W I Lio

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

M F Lam

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

T M Chan

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, dtmchan{at}hkucc.hku.hk

There is accumulating evidence that mycophenolate mofetil (MMF), when combined with corticosteroid, is an effective induction treatment for severe proliferative lupus nephritis and is associated with fewer adverse effects compared to cyclophosphamide (CTX), but the quality of life (QOL) associated with these regimens as perceived by the patient has not been compared.

This study included patients who had experienced both treatment regimens, for distinct episodes of diffuse proliferative lupus nephritis. QOL parameters during the first six months of each treatment were assessed through SF36 and WHOQOL questionnaires.

Twelve patients and 24 episodes of severe lupus nephritis were studied. CTX-treated and MMF-treated episodes showed comparable baseline characteristics and response rate, with complete remission occurring in 83.3%. MMF treatment was associated with higher numerical scores for all domains across both QOL instruments than CTX. MMF treatment was associated with significantly less fatigue, less impediment of physical and social functioning, and better psychological well being compared to CTX. When each patient served as her/his own control, most patients ascribed higher QOL domain scores to the MMF-treated episode. Seventy-five percent of patients found MMF treatment more acceptable and preferred when compared with CTX, and the complications that most concerned them included Cushingoid features, alopecia, menstrual disturbance and infections.

These data showed that MMF-based induction immunosuppression for severe lupus nephritis was associated with better QOL than CTX as perceived by patients, which was most likely attributed to the reduced side-effects during MMF treatment.

Key Words: cyclophosphamide • lupus nephritis • mycophenolate mofetil • quality of life • SF36 • WHOQOL

Lupus, Vol. 15, No. 6, 371-379 (2006)
DOI: 10.1191/0961203306lu2307xx


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Kriegel, C Van Beek, A Mostaghimi, and V. Kyttaris Sterile empyematous pleural effusion in a patient with systemic lupus erythematosus: a diagnostic challenge Lupus, June 1, 2009; 18(7): 581 - 585. [Abstract] [PDF]

				S. APPENZELLER, A. E. CLARKE, P. PANOPALIS, L. JOSEPH, Y. ST. PIERRE, and T. LI The Relationship Between Renal Activity and Quality of Life in Systemic Lupus Erythematosus J Rheumatol, May 1, 2009; 36(5): 947 - 952. [Abstract] [Full Text] [PDF]

				K. C. TSE, C. S.O. TANG, M. F. LAM, D. Y.H. YAP, and T. M. CHAN Cost Comparison Between Mycophenolate Mofetil and Cyclophosphamide-Azathioprine in the Treatment of Lupus Nephritis J Rheumatol, January 1, 2009; 36(1): 76 - 81. [Abstract] [Full Text] [PDF]

				T. Chan Mycophenolate mofetil in the treatment of lupus nephritis - 7 years on Lupus, July 1, 2008; 17(7): 617 - 621. [PDF]

				A. E. Clarke, P. Panopalis, M. Petri, S. Manzi, D. A. Isenberg, C. Gordon, J.-L. Senecal, L. Joseph, Y. St Pierre, and T. Li SLE patients with renal damage incur higher health care costs Rheumatology, March 1, 2008; 47(3): 329 - 333. [Abstract] [Full Text] [PDF]